Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMD7L94)

Drug Name
Palbociclib Drug Info
Synonyms
571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
5330286
ChEBI ID
CHEMBL189963
CAS Number
CAS 571190-30-2
TTD Drug ID
D00UZR
VARIDT Drug ID
DR01288
INTEDE Drug ID
DR1229
ACDINA Drug ID
D00504

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Complement and coagulation cascades 2.03 0.00e+0 76/85 (89.41%) CFB;C3;CFI;...
Valine, leucine and isoleucine degradation 1.95 0.00e+0 42/48 (87.5%) ABAT;HMGCS1;ACAA1;...
Mineral absorption 1.88 1.53e-2 48/60 (80%) STEAP1;ATP7B;SLC30A1;...
ECM-receptor interaction 1.87 1.15e-2 80/88 (90.91%) LAMC2;COL4A5;ITGAV;...
Propanoate metabolism 1.86 9.19e-3 30/34 (88.24%) ABAT;ACACA;PCCB;...
Malaria 1.80 2.04e-2 44/50 (88%) IL1B;CCL2;MET;...
Coronavirus disease 1.80 1.75e-2 215/232 (92.67%) CFB;ISG15;IL1B;...
Pertussis 1.73 3.25e-2 64/76 (84.21%) IL1B;C3;PYCARD;...
NOD-like receptor signaling pathway 1.71 3.91e-2 145/181 (80.11%) IL1B;CCL2;OAS1;...
Cytosolic DNA-sensing pathway 1.69 4.44e-2 52/63 (82.54%) IL1B;CXCL10;PYCARD;...
Fatty acid degradation 1.69 4.04e-2 40/43 (93.02%) ACAA1;ALDH2;ALDH1B1;...
N-Glycan biosynthesis 1.69 3.70e-2 38/50 (76%) FUT8;MAN1A2;DPM3;...
Rheumatoid arthritis 1.68 4.12e-2 78/93 (83.87%) IL1B;CCL2;CCL20;...
Steroid biosynthesis 1.67 4.48e-2 19/20 (95%) MSMO1;LIPA;DHCR24;...
Cytokine-cytokine receptor interaction 1.67 4.18e-2 246/295 (83.39%) IL1B;TNFRSF10B;CXCL10;...
Viral protein interaction with cytokine and cytokine re... 1.66 4.31e-2 84/100 (84%) TNFRSF10B;CXCL10;CXCL11;...
beta-Alanine metabolism 1.66 4.05e-2 25/30 (83.33%) ABAT;CNDP2;ALDH2;...
Thiamine metabolism 1.66 4.08e-2 12/15 (80%) NFS1;AK2;AK4;...
Leishmaniasis 1.63 4.92e-2 67/77 (87.01%) IL1B;C3;IL1A;...
PPAR signaling pathway 1.63 4.82e-2 66/74 (89.19%) ME1;HMGCS1;ACAA1;...
Mucin type O-glycan biosynthesis 1.63 4.59e-2 20/36 (55.56%) GALNT7;GALNT2;GALNT11;...
Amoebiasis 1.62 4.80e-2 99/102 (97.06%) LAMC2;IL1B;COL4A5;...
Glycolysis / Gluconeogenesis 1.61 4.86e-2 56/67 (83.58%) ALDH2;BPGM;PGM1;...
Other types of O-glycan biosynthesis 1.61 4.91e-2 29/47 (61.7%) GALNT7;GALNT2;GALNT11;...
Pyruvate metabolism 1.61 4.72e-2 41/47 (87.23%) ME1;ACACA;ALDH2;...
Toll-like receptor signaling pathway 1.60 4.83e-2 94/104 (90.38%) IL1B;CXCL10;CXCL11;...
Influenza A 1.60 4.71e-2 156/172 (90.7%) IL1B;TNFRSF10B;CXCL10;...
Cellular senescence -1.70 2.36e-2 139/156 (89.1%) PPP1CA;MAPK14;PTEN;...
RNA degradation -1.71 2.32e-2 53/79 (67.09%) ENO1;CNOT8;TENT4A;...
MicroRNAs in cancer -1.71 2.49e-2 146/310 (47.1%) PIK3CA;CCNE1;APC;...
mRNA surveillance pathway -1.75 1.45e-2 71/98 (72.45%) PCF11;PAPOLA;SMG6;...
p53 signaling pathway -1.90 1.09e-3 63/73 (86.3%) CASP3;PTEN;CDK4;...
Base excision repair -2.00 0.00e+0 29/33 (87.88%) PARP1;POLD3;POLD2;...
Mismatch repair -2.07 0.00e+0 22/23 (95.65%) RFC1;RPA1;POLD3;...
Nucleotide excision repair -2.09 0.00e+0 40/47 (85.11%) RFC1;RPA1;RAD23B;...
Homologous recombination -2.17 0.00e+0 35/41 (85.37%) RPA2;TOPBP1;RPA1;...
Spliceosome -2.20 0.00e+0 101/150 (67.33%) SNRPG;TCERG1;ACIN1;...
Oocyte meiosis -2.30 0.00e+0 90/129 (69.77%) PPP1CA;MAPK14;PPP2R5C;...
Progesterone-mediated oocyte maturation -2.33 0.00e+0 75/100 (75%) RAF1;ADCY1;HSP90AA1;...
Fanconi anemia pathway -2.40 0.00e+0 36/54 (66.67%) FANCL;FANCC;RPA1;...
DNA replication -2.52 0.00e+0 34/36 (94.44%) RFC1;RPA1;POLD3;...
Cell cycle -2.68 0.00e+0 110/124 (88.71%) RB1;SKP2;TP53;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 0.12uM - 10uM 24H
TC-32 CVCL_7141 Homo sapiens 0.12uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Brain
Glioblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-251 MG CVCL_0021 Homo sapiens 0.12uM - 10uM 24H
YH-13 CVCL_1800 Homo sapiens 0.12uM - 10uM 24H
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 0.12uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 0.12uM - 10uM 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-474 CVCL_0179 Homo sapiens 0.12uM - 10uM 24H
T-47D CVCL_0553 Homo sapiens 0.12uM - 10uM 24H
ZR-75-1 CVCL_0588 Homo sapiens 0.12uM - 10uM 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 3H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GP2d CVCL_1234 Homo sapiens 0.12uM - 10uM 24H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 0.12uM - 10uM 24H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WA09 (H9) Derived CVCL_9773 (WA09) Homo sapiens 0.12uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-151 CVCL_2927 Homo sapiens 0.12uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 0.12uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 0.12uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 0.12uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 0.12uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Renal cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RCC10RGB CVCL_1656 Homo sapiens 0.12uM - 10uM 24H
Rhabdoid tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
G-401 CVCL_0270 Homo sapiens 0.12uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 0.12uM - 10uM 24H
JHH-7 CVCL_1322 Homo sapiens 0.12uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
NCI-H1437 CVCL_1472 Homo sapiens 0.12uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 0.12uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 0.12uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 0.12uM - 10uM 24H
HCC1588 CVCL_1263 Homo sapiens 0.12uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 0.12uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
NCI-H2110 CVCL_1529 Homo sapiens 0.12uM - 10uM 24H
NCI-H2172 CVCL_1534 Homo sapiens 0.12uM - 10uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H841 CVCL_1595 Homo sapiens 0.12uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 0.12uM - 10uM 24H
Oral cavity
Oral squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BICR 6 CVCL_1086 Homo sapiens 0.12uM - 10uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVK18 CVCL_1629 Homo sapiens 0.12uM - 10uM 24H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ES-2 CVCL_3509 Homo sapiens 0.12uM - 10uM 24H
OVTOKO CVCL_3114 Homo sapiens 0.12uM - 10uM 24H
Ovarian cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OAW 28 CVCL_1611 Homo sapiens 0.12uM - 10uM 24H
OC 316 CVCL_1615 Homo sapiens 0.12uM - 10uM 24H
Ovarian endometrioid carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TOV-112D CVCL_3612 Homo sapiens 0.12uM - 10uM 24H
Ovarian granulosa cell tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV434 CVCL_2010 Homo sapiens 0.12uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 6H, 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 0.12uM - 10uM 24H
LNCaP CVCL_0395 Homo sapiens 0.04uM - 10uM 3H, 24H
LNCaP clone FGC CVCL_1379 Homo sapiens 0.12uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 0.12uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 0.12uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 0.12uM - 10uM 24H
SK-MEL-3 CVCL_0525 Homo sapiens 0.12uM - 10uM 24H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.12uM - 1.11uM 24H
MKN45 CVCL_0434 Homo sapiens 0.12uM - 10uM 24H
Gastric carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IM95 CVCL_1305 Homo sapiens 0.12uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 0.12uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 0.12uM - 10uM 24H